



26 March 2020  
EMA/158954/2020  
Human Medicines Division

## Overview of (invented) names reviewed in February 2020 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 23-26 March 2020

	NRG meeting 25-26 Feb 2020		NRG meeting 23 Apr 2020		NRG meeting 02-03 June 2020		NRG meeting 15-16 Sep 2020		NRG meeting 24-25 Nov 2020		2020 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	44	69			-	-	-	-	-	-	<b>44</b>	<b>69</b>
Justification for retention of (invented) name **	6	11			-	-	-	-	-	-	<b>6</b>	<b>11</b>

\*Includes invented names, INN+MAH/TM and re-use applications.

\*\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 26-27 Feb 2019		NRG meeting 21-22 May 2019		NRG meeting 18 Sep 2019		NRG meeting 22 Nov 2019		2019	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	141	213	-	-	-	-	-	-	141	213
<b>Criterion - Safety concerns</b>										
Similarity with other (invented) name	115	154	-	-	-	-	-	-	115	154
Conveys misleading therapeutic/pharmaceutical connotations	2	6	-	-	-	-	-	-	2	6
Misleading with respect to composition	0	0	-	-	-	-	-	-	0	0
<b>Criterion - INN concerns</b>										
Similarity with INN	7	1	-	-	-	-	-	-	7	1
Inclusion of INN stem	2	0	-	-	-	-	-	-	2	0
<b>Criterion - Other public health concerns</b>										
Unacceptable qualifiers	0	0	-	-	-	-	-	-	0	0
Conveys a promotional message	4	5	-	-	-	-	-	-	4	5
Appears offensive or has an inappropriate connotation	0	1	-	-	-	-	-	-	0	1
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	-	-	-	-	-	-	0	0
Similarity between name of prodrug and related active substance	0	0	-	-	-	-	-	-	0	0
Others	11	46	-	-	-	-	-	-	11	46

See Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#) for detailed explanations of criteria used.